Rifampicin mono-resistant tuberculosis in France: A 2005-2010 retrospective cohort analysis

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Meyssonnier, Vanina ^a,b   Bui, Thuy V ^a,c   Veziris, Nicolas ^a,c,d   Jarlier, Vincent ^a,c,d   Robert, Jérôme ^a,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Management; Monoresistance; Mycobacterium tuberculosis; Rifampicin

Indexed keywords

ALCOHOL; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CIPROFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DEATH; DEMOGRAPHY; DRUG RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; FRANCE; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; QUESTIONNAIRE; RELAPSE; RETROSPECTIVE STUDY; RIFAMPICIN MONO RESISTANT TUBERCULOSIS; SMEAR; TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; COMPLICATION; MIDDLE AGED; MIXED INFECTION; RISK FACTOR; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; COINFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; FRANCE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFAMPIN; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84892407318     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-18     Document Type: Article

References (36)

1. World Health Organization Global tuberculosis report 2013. http://www.who.int/tb/publications/global_report/en/, World Health Organization.
2. American Thoracic Society, Centers for Disease Control and Prevention Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000, 161:1376-1395. American Thoracic Society, Centers for Disease Control and Prevention.
3. Meyssonnier V, Veziris N, Bastian S, Texier-Maugein J, Jarlier V, Robert J. Increase in primary drug resistance of Mycobacterium tuberculosis in younger birth cohorts in France. J Infect 2012, 64:589-595.
4. Ridzon R, Whitney CG, McKenna MT, Taylor JP, Ashkar SH, Nitta AT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998, 157:1881-1884.
5. Khuê PM, Truffot-Pernot C, Texier-Maugein J, Jarlier V, Robert J. A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995-2004. Eur Respir J 2007, 30:937-944.
6. Porco TC, Oh P, Flood JM. Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006. Clin Infect Dis 2013, 56:761-769.
7. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 2011, 53:369-372.
8. Bang D, Andersen PH, Andersen AB, Thomsen V. Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. J Infect 2010, 60:452-457. 10.1016/j.jinf.2010.03.017.
9. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009, 6:e1000150.
10. Singla R, Al-Sharif N, Al-Sayegh MO, Osman MM, Shaikh MA. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Int J Tuberc Lung Dis 2002, 6:585-591.
11. Centers for Disease Control and Prevention Treatment of tuberculosis, American thoracic society, CDC, and infectious diseases society of america. MMWR 2003, 52(RR-11):1-77. Centers for Disease Control and Prevention.
12. Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. WHO/HTM/TB/2011.6.2011: [http://www.who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb/en/].
13. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO. WHO/HTM/TB/2008.402. http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf.
14. Caminero JA. Guidelines for the Clinical and Operational Management of drug-resistant Tuberculosis 2013, Paris, France: International Union Against Tuberculosis and Lung Disease, http://www.theunion.org/what-we-do/publications/technical/guidelines-for-the-clinical-and-operational-management-of-drug-resistant-tuberculosis.
15. Robert J, Trystram D, Truffot-Pernot C, Jarlier V. Multidrug-resistant tuberculosis: eight years of surveillance in France. Eur Respir J 2003, 22:833-837.
16. Brossier F, Veziris N, Jarlier V, Sougakoff W. Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosisresistance to isoniazid. Int J Tuberc Lung Dis 2009, 13:260-265.
17. Epidemiology of tuberculosis in the EU/EEA in 2010 - monitoring the progress towards tuberculosis elimination. [http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20124].
18. Mulenga C, Chonde A, Bwalya IC, Kapata N, Kakungu-Simpungwe M, Docx S, et al. Low occurrence of tuberculosis drug resistance among pulmonary tuberculosis patients from an urban setting, with a long-running DOTS program in Zambia. Tuberc Res Treat 2010, 2010:938178.
19. Mukinda FK, Theron D, Van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, et al. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis 2012, 16:196-202.
20. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005, 41:83-91.
21. Lutfey M, Della-Latta P, Kapur V, Palumbo LA, Gurner D, Stotzky G, et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996, 153:837-840.
22. Sandman L, Schluger NW, Davidow AL, Bonk S. Risk factors for rifampin-monoresistant tuberculosis: a case-control study. Am J Respir Crit Care Med 1999, 159:468-472.
23. Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997, 25:1465-1467.
24. Veziris N, Jarlier V, Robert J. Resistance to anti-tuberculosis drugs in France, 2009-2010. Bull Epidemiol Hebdo 2012, 24-25:291-293.
25. Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent tuberculosis infection treatment acceptance and completion in the United States and Canada. Chest 2010, 137:401-409.
26. Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis 2010, 14:1104-1111.
27. Pablos-Méndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997, 102:164-170.
28. Srivastava S, Sherman C, Meek C, Leff R, Gumbo T. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother 2011, 55:5085-5089.
29. Dramowski A, Morsheimer MM, Jordaan AM, Victor TC, Donald PR, Schaaf HS. Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa. Int J Tuberc Lung Dis 2012, 16:76-81.
30. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 1999, 160:587-593.
31. Uffredi M-L, Truffot-Pernot C, Dautzenberg B, Renard M, Jarlier V, Robert J. An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents 2007, 29:434-439.
32. Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. Study of the rifampin mono-resistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013, 57:893-900.
33. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997, 41:2670-2679.
34. Poissy J, Aubry A, Fernandez C, Lott M-C, Chauffour A, Jarlier V, et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010, 54:4765-4771.
35. Törün T, Tahaoǧlu K, Ozmen I, Sevim T, Ataç G, Kir A, et al. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2007, 11:979-985.
36. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9:e1001300.